In-stent restenosis is inhibited in a bare metal stent implanted distal to a sirolimus-eluting stent to treat a long de novo coronary lesion with small distal vessel diameter

Catheterization and Cardiovascular Interventions

Volumn 82, Issue 6, 2013, Pages

  Obata, Jyun Ei ^a   Nakamura, Takamitsu ^a   Kitta, Yoshinobu ^a   Saito, Yukio ^a   Sano, Keita ^a   Fujioka, Daisuke ^a   Kawabata, Ken Ichi ^a   Kugiyama, Kiyotaka ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

coronary artery disease (CAD); percutaneous coronary intervention (PCI); quantitative coronary angiography (QCA); restenosis (RSTN)

Indexed keywords

RAPAMYCIN; CARDIOVASCULAR AGENT; METAL;

AGED; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; CORONARY STENT; DRUG ELUTING STENT; FEMALE; HUMAN; IN-STENT RESTENOSIS; INTERMETHOD COMPARISON; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; NEOINTIMA; OUTCOME ASSESSMENT; TREATMENT OUTCOME; ADVERSE EFFECTS; CELL PROLIFERATION; COMPARATIVE STUDY; CORONARY ANGIOGRAPHY; CORONARY BLOOD VESSEL; CORONARY RESTENOSIS; DEVICES; DRUG EFFECTS; ECHOGRAPHY; INTERVENTIONAL ULTRASONOGRAPHY; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; PROSTHESIS DESIGN; RADIOGRAPHY; SEVERITY OF ILLNESS INDEX; STENT; TIME FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR AGENTS; CELL PROLIFERATION; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; CORONARY VESSELS; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; METALS; NEOINTIMA; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; SEVERITY OF ILLNESS INDEX; SIROLIMUS; STENTS; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84887321684     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.24841     Document Type: Article

References (27)

1. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R,; RAVEL Study Group. Randomized study with the sirolimus-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780.
2. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE,; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
3. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenbertg J, Popma JJ, Russell ME, for the TAXUS-IV Investigators. A polymer-based paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231.
4. Lemos PA, Serruys PW, van Domburg RT, Saia F, Arampatzis CA, Hoye A, Degertekin M, Tanabe K, Daemen J, Liu TKK, McFadden E, Sianos G, Hofma SH, Smits PC, van der Giessen WJ, de Feyter PJ,. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "Real World". The Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004; 109: 190-195.
5. Moses JW, Nikolsky E, Mehran R, Cambier PA, Bachinsky WB, Leya F, Kuntz RE, Popma JJ, Schleckser P, Wang H, Cohen SA, Leon MB, for the SIRIUS 2.25 Investigators. Safety and efficacy of the 2.25-mm sirolimus-eluting Bx Velocity stent in the treatment of patients with de novo native coronary artery lesions: the SIRIUS 2.25 trial. Am J Cardiol 2006; 98: 1455-1460.
6. Ong AT, Serruys PW, Aoki J, Hoye A, van Mieghem CA, Rodriguez-Granillo GA, Valgimigli M, Sonnenschein K, Reger E, van der Ent M, de Jaegere PP, McFadden EP, Sianos G, van der Giessen WJ, de Feyter PJ, van Domburg RT,. The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: One-year results of the Taxus-Stent Evaluated At Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol 2005; 45: 1135-1141.
7. Umeda H, Iwase M, Gochi T, Izawa H, Ishiki R, Inagaki H, Shimizu T, Yokota M, Murohara T,. Safety and efficacy of 2.5-mm sirolimus-eluting stent implantation at lower deployment pressures in very small vessels (<2.5 mm). Coron Artery Dis 2009; 20: 163-168.
8. Klugherz BD, Llanos G, Lieuallen W, Kopia GA, Papandreou G, Narayan P, Sasseen B, Adelman SJ, Falotico R, Wilensky RL,. Twenty-eight-day efficacy and pharmacokinetics of the sirolimus-eluting stent. Coron Artery Dis 2002; 13: 183-188.
9. Otsuka Y, Nakamura M, Yasuda S, Kozuma K, Hara H, Morii I, Kawamura A, Sase K, Miyazaki S,. Comparison of pharmacokinetics of the sirolimus-eluting stent in Japanese patients with those in American patients. J Cardiovasc Pharmacol 2005; 46: 468-473.
10. Vetrovec GW, Rizik D, Williard C, Snead D, Piotrovski V, Kopia G,. Sirolimus PK trail: A pharmacokinetic study of the sirolimus-eluting Bx Velocity stent in patients with de novo coronary lesions. Cathet Cardiovasc Intervent 2006; 67: 32-37.
11. Obata JE, Kitta Y, Takano H, Kodama Y, Nakamura T, Mende A, Kawabata KI, Saitoh Y, Fujioka D, Kobayashi T, Yano T, Kugiyama K,. Sirolimus-eluting stent implantation aggravates endothelial vasomotor dysfunction in the infarct-related coronary artery in patients with acute myocardial infarction. J Am Coll Cardiol 2007; 50: 1305-1309.
12. Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, Jorgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, Stone GW, Wijns W, Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. Eur Heart J 2005; 26: 804-847.
13. Dussaillant GR, Mintz GS, Pichard AD, Kent KM, Satler LF, Popma JJ, Wong SC, Leon MB,. Small stent size and intimal hyperplasia contribute to restenosis: A volumetric intravascular ultrasound analysis. J Am Coll Cardiol 1995; 26: 720-724.
14. Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, Pichard AD, Kent KM, Stone GW, Leon MB,. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 1999; 100: 1872-1878.
15. Wentzel JJ, Krams R, Schuurbiers JC, Oomen JA, Kloet J, van Der Giessen WJ, Serruys PW, Slager CJ,. Relationship between neointimal thickness and shear stress after wallstent implantation in human coronary arteries. Circulation 2001; 103: 1740-1745.
16. Malek AM, Alper SL, Izumo S,. Hemodynamic shear stress and its role in atherosclerosis. JAMA 1999; 282: 2035-2042.
17. Balakrishnan B, Tzafriri AR, Seifert P, Groothuis A, Rogers C, Edelman ER,. Strut position, blood flow, and drug deposition: Implications for single and overlapping drug-eluting stents. Circulation 2005; 111: 2958-2965.
18. Obata JE, Nakamura T, Kitta Y, Kodama Y, Sano K, Kawabata KI, Saitoh Y, Fujioka D, Kobayashi T, Yano T, Watanabe Y, Watanabe K, Kugiyama K,. Treatment of acute myocardial infarction with sirolimus-eluting stents results in chronic endothelial dysfunction in the infarct-related coronary artery. Circ Cardiovasc Intervent 2009; 2: 384-391.
19. Nakazawa G, Otsuka F, Nakano M, Vorpohl M, Yazdani SK, Ladich E, Kolodgie FD, Finn AV, Virmarn R,. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 2011; 57: 1314-1322.
20. Krasuski RA, Cater GM, Devendra GP, Wolski K, Shishehbor MH, Nissen SE, Oberti C, Ellis SG,. Downstream coronary effects of drug-eluting stents. Am Heart J 2011; 162: 764-771.
21. Ma KL, Ruan XZ, Powis SH, Moorhead JF, Varghese Z,. Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2007; 292: H2721-H2728.
22. Corbett SJ, Cosgrave J, Melzi G, Babic R, Biondi-Zoccai GG, Godino C, Morici N, Airoldi F, Michev I, Montorfano M, Sangiorgi GM, Bonizzoni E, Colombo A,. Patterns of restenosis after drug-eluting stent implantation: Insights from a contemporary and comparative analysis of sirolimus- and paclitaxel-eluting stents. Eur Heart J 2006; 19: 2330-2337.
23. Berry JL, Santamarina A, Moore JE Jr, Roychowdhury S, Routh WD,. Experimental and computational flow evaluation of coronary stents. Ann Biomed Eng 2000; 28: 386-398.
24. Kronsteiner E, Lee RW, Sweeney JP, Metallo JR, Stoehr JD, Fortuin FD,. Outcomes of overlapping bare-metal stents with sirolimus-eluting stents for long lesions in small coronary vessels. J Invasive Cardiol 2010; 22: 76-79.
25. Aoki J, Kirtane AJ, Dangas GD, Lansky AJ, Morales A, Kimura M, Kim YH, Moussa I, Weisz G, Kreps EM, Collins M, Frankin-Bond T, Stone GW, Moses JW, Leon MB, Mehran R,. Clinical outcomes after heterogeneous overlap stenting with drug-eluting stents and bare-metal stents for de novo coronary artery narrowings. Am J Cardiol 2008; 101: 58-62.
26. Burzotta F, Siviglia M, Altamura L, Trani C, Leone AM, Romagnoli E, Attilio M, Mongiardo R, Giampaolo N, Brancati M, Biondi-Zoccai G, Rebuzzi AG, Schiavoni G, Crea F,. Outcome of overlapping heterogeneous drug-eluting stents and of overlapping drug-eluting and bare metal stents. Am J Cardiol 2007; 99: 364-368.
27. Takano M, Murakami D, Mizuno K,. Overlapping hybrid stenting with a sirolimur-eluting stent and a bare metal stent. Int J Cardiol 2007; 118: e8-e10.